Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote,Antonio González-Martín,Keiichi Fujiwara,Elsa Kalbacher,Andrea Bagaméri,Sharad Ghamande,Jung-Yun Lee,Susana Banerjee,Fernando Cotait Maluf,Domenica Lorusso,Kan Yonemori,Els Van Nieuwenhuysen,Luis Manso,Linn Woelber,Anneke Westermann,Allan Covens,Kosei Hasegawa,Byoung-Gie Kim,Miriam Raimondo,Maria Bjurberg,Felipe Melo Cruz,Antoine Angelergues,David Cibula,Lisa Barraclough,Ana Oaknin,Christine Gennigens,Leo Nicacio,Melinda Siew Leng Teng,Elizabeth Whalley,Ibrahima Soumaoro,Brian M Slomovitz,innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators,Krishnansu Tewari,Charles Leath,Leslie Boyd,Linda Van Le,Casey Cosgrove,Linda Duska,Scott Jordan,Lisa Barroilhet,Christine Holschneider,Premal Thaker,Peter Rose,Mary Gordinier,Dario Roque,David Fishman,Christen Walters Haygood,Leslie Randall,Alessandro Santin,Bradley Monk,Michael Teneriello,Jessica Thomes-Pepin,Charles Anderson,Joseph Buscema,Noelle Cloven,Christine Lee,Destin Black,Cheryl Aylesworth,Erin Salinas,Anna Priebe,Michael McCollum,Thomas Reid,Michael Kolinsky,Stephanie Lheureux,Anna Tinker,M Laura Hopkins,Vanessa Samouelian,Roy Lalisang,P B Nelleke Ottevanger,Ingrid Boere,Petronella Witteveen,Jean-François Baurain,Hannelore Denys,Stephanie Henry,Brigitte Honhon,Laura Polastro,Wesley Teurfs,Coriolan Lebreton,Laurence Gladieff,Florence Joly,Alexandra Leary,Alain Lortholary,Lauriane Eberst,Anne-Claire Hardy-Bessard,Marie-Christine Kaminsky,Jose Alejandro Perez Fidalgo,Lydia Gava Garcia,Antonio Gonzalez Martin,Maria Rubio Perez,Ana Oaknin Benzaquen,Luis Manuel Manso Sanchez,Andres Redondo Sanchez,Paula Calvert,Maarit Anttila,Sakari Hietanen,Annika Auranen,Andrea Bagameri,Robert Poka,Judit Kocsis,Ugo De Giorgi,Giorgia Mangili,Rocco De Vivo,Paolo Scollo,Marketa Bednarikova,Bohuslav Melichar,Michal Zikan,Edgar Petru,Stephan Polterauer,Jenny Forrest,Azmat Sadozye,Joo Ern Ang,Mansoor Mirza,Anthoula Koliadi,Gabriel Lindahl,Kristina Lindemann,Marit Sundset,Beata Mackowiak-Matejczyk,Pawel Mach,Florian Heitz,Fabian Trillsch,Ana Calle,Jessica Reyes Contreras,Natalia Laura Baltz Hehn,Miriam Gabriela Raimondo,Gonzalo Giornelli,Matias Molina,Felipe Cruz,Fernanda Damian,Andreia Melo,Fernando Maluf,Joao Lima,Reitan Ribeiro,Fabio Franke,Christina Pimenel Oppermann,Wen Yee Chay,Yi Wan Lim,Shoji Kamiura,Takashi Matsumoto,Toshiaki Nakamura,Takashi Iwata,Satoshi Yamaguchi,Kazuto Nakamura,Hidemichi Watari,Aikou Okamoto,Akira Kikuchi,Shin Nishio,Etsuko Miyagi,Noriyuki Katsumata,Kazuhiro Takehara,Shiro Suzuki,Hiroko Nakamura,Yusuke Taira,Ayako Mochizuki,Hidekatsu Nakai,Shoji Nagao,Tsukasa Baba,Kenichi Harano,Yoichi Aoki,Hiroaki Kobayashi,Hidenori Kato,Hisamori Kato,Hirokuni Takano,Jae-Weon Kim,Seob Jeon,Myong Cheol Lim,Jae Hong No,Min Kyu Kim,JaeHoon Kim,Min Chul Choi,Yun Hwan Kim,Moon-Hong Kim,Daehoon Jeong,Sung Jong Lee,Yong Man Kim,So Jin Shin,Guiling Li,Qi Zhou,Lingying Wu,Lihong Chen,Jianliu Wang,Angel Chao,Peng-Hui Wang,Chih-Long Chang,Annouschka Laenen
DOI: https://doi.org/10.1056/NEJMoa2313811
2024-07-04
Abstract:Background: Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy. Methods: We conducted a phase 3, multinational, open-label trial of tisotumab vedotin as second- or third-line therapy in patients with recurrent or metastatic cervical cancer. Patients were randomly assigned, in a 1:1 ratio, to receive tisotumab vedotin monotherapy (2.0 mg per kilogram of body weight every 3 weeks) or the investigator's choice of chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary end point was overall survival. Results: A total of 502 patients underwent randomization (253 were assigned to the tisotumab vedotin group and 249 to the chemotherapy group); the groups were similar with respect to demographic and disease characteristics. The median overall survival was significantly longer in the tisotumab vedotin group than in the chemotherapy group (11.5 months [95% confidence interval {CI}, 9.8 to 14.9] vs. 9.5 months [95% CI, 7.9 to 10.7]), results that represented a 30% lower risk of death with tisotumab vedotin than with chemotherapy (hazard ratio, 0.70; 95% CI, 0.54 to 0.89; two-sided P = 0.004). The median progression-free survival was 4.2 months (95% CI, 4.0 to 4.4) with tisotumab vedotin and 2.9 months (95% CI, 2.6 to 3.1) with chemotherapy (hazard ratio, 0.67; 95% CI, 0.54 to 0.82; two-sided P<0.001). The confirmed objective response rate was 17.8% in the tisotumab vedotin group and 5.2% in the chemotherapy group (odds ratio, 4.0; 95% CI, 2.1 to 7.6; two-sided P<0.001). A total of 98.4% of patients in the tisotumab vedotin group and 99.2% in the chemotherapy group had at least one adverse event that occurred during the treatment period (defined as the period from day 1 of dose 1 until 30 days after the last dose); grade 3 or greater events occurred in 52.0% and 62.3%, respectively. A total of 14.8% of patients stopped tisotumab vedotin treatment because of toxic effects. Conclusions: In patients with recurrent cervical cancer, second- or third-line treatment with tisotumab vedotin resulted in significantly greater efficacy than chemotherapy. (Funded by Genmab and Seagen [acquired by Pfizer]; innovaTV 301 ClinicalTrials.gov number, NCT04697628.).